ANXA8L1

Across TCGA pan-cancer cohorts, ANXA8L1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANXA8L1 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANXA8L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANXA8L1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where ANXA8L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.333	0.912	.009	33	view →
LSCC	OS	Median	All	0.700	0.885	.022	5	view →
PDAC	OS	Median	II,III,IV	0.395	0.596	.028	4	view →
CCRCC	OS	Quartile	II,III,IV	0.191	1.000	.020	2	view →
HNSC	OS	Tertile	All	0.893	0.769	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANXA8L1–LUAD (OS)

Open the LUAD breakdown →